Display options
Cite
Corren J, Saini SS, Gagnon R, et al. Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial. J Asthma Allergy. 2021;14:1045-1063doi: 10.2147/JAA.S318892.
Corren, J., Saini, S. S., Gagnon, R., Moss, M. H., Sussman, G., Jacobs, J., Laws, E., Chung, E. S., Constant, T., Sun, Y., Maloney, J., Hamilton, J. D., Ruddy, M., Wang, C. Q., & O'Brien, M. P. (2021). Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial. Journal of asthma and allergy, 141045-1063. https://doi.org/10.2147/JAA.S318892
Corren, Jonathan, et al. "Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial." Journal of asthma and allergy vol. 14 (2021): 1045-1063. doi: https://doi.org/10.2147/JAA.S318892
Corren J, Saini SS, Gagnon R, Moss MH, Sussman G, Jacobs J, Laws E, Chung ES, Constant T, Sun Y, Maloney J, Hamilton JD, Ruddy M, Wang CQ, O'Brien MP. Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial. J Asthma Allergy. 2021 Aug 16;14:1045-1063. doi: 10.2147/JAA.S318892. eCollection 2021. PMID: 34429614; PMCID: PMC8379710.
Copy Download .nbib Format: NLM
Share it on

J Asthma Allergy. 2021 Aug 16;14:1045-1063. doi: 10.2147/JAA.S318892. eCollection 2021.

Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial.

Journal of asthma and allergy

Jonathan Corren, Sarbjit S Saini, Remi Gagnon, Mark H Moss, Gordon Sussman, Joshua Jacobs, Elizabeth Laws, Elinore S Chung, Tatiana Constant, Yiping Sun, Jennifer Maloney, Jennifer D Hamilton, Marcella Ruddy, Claire Q Wang, Meagan P O'Brien

Affiliations

  1. Departments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  2. Department of Internal Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA.
  3. Clinique Spécialisée en Allergie de la Capitale, Québec, QC, Canada.
  4. Departments of Medicine and Pediatrics, Division of Allergy, Pulmonary and Critical Care, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  5. Department of Medicine, University of Toronto, Toronto, ON, Canada.
  6. Allergy and Asthma Clinical Research, Inc, Walnut Creek, CA, USA.
  7. Sanofi, Bridgewater, NJ, USA.
  8. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.

PMID: 34429614 PMCID: PMC8379710 DOI: 10.2147/JAA.S318892

Abstract

BACKGROUND: Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases.

OBJECTIVE: To evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone.

METHODS: This phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0-1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17.

RESULTS: Although 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0-1 h) following NAC at Week 17 vs SCIT (least squares mean -56.76% vs -52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%];

CONCLUSION: In SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone.

CLINICAL STUDY NUMBER: NCT03558997.

© 2021 Corren et al.

Keywords: dupilumab; nasal allergen responses; seasonal allergic rhinitis; subcutaneous immunotherapy

References

  1. J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):161-7 - PubMed
  2. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):464-475 - PubMed
  3. Science. 2018 Dec 14;362(6420):1306-1309 - PubMed
  4. Allergy. 2019 Apr;74(4):743-752 - PubMed
  5. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55 - PubMed
  6. Lancet. 2019 Nov 2;394(10209):1638-1650 - PubMed
  7. Br J Dermatol. 2018 May;178(5):1083-1101 - PubMed
  8. J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):84-89.e3 - PubMed
  9. JAMA. 2017 Feb 14;317(6):615-625 - PubMed
  10. Sci Transl Med. 2017 Aug 2;9(401): - PubMed
  11. Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1-43 - PubMed
  12. Lancet. 2017 Jun 10;389(10086):2287-2303 - PubMed
  13. Clin Exp Allergy. 2006 Mar;36(3):254-60 - PubMed
  14. Allergy. 2017 Dec;72(12):1825-1848 - PubMed
  15. N Engl J Med. 2018 Jun 28;378(26):2486-2496 - PubMed
  16. J Allergy Clin Immunol. 1982 Oct;70(4):261-71 - PubMed
  17. Allergy. 2020 May;75(5):1188-1204 - PubMed
  18. Allergol Int. 2020 Oct;69(4):549-560 - PubMed
  19. Ann Allergy Asthma Immunol. 2011 Nov;107(5):441-7 - PubMed
  20. N Engl J Med. 1999 Aug 12;341(7):468-75 - PubMed
  21. J Immunol. 1990 Dec 1;145(11):3796-806 - PubMed
  22. Immunol Lett. 2020 Nov;227:81-87 - PubMed
  23. Allergy. 2020 Oct;75(10):2653-2661 - PubMed
  24. Allergy. 2012 Feb;67(2):217-26 - PubMed
  25. Am J Otolaryngol. 2019 Nov - Dec;40(6):102269 - PubMed
  26. Ann Allergy Asthma Immunol. 2020 Nov;125(5):565-576.e1 - PubMed
  27. Int Arch Allergy Immunol. 2021;182(6):553-561 - PubMed
  28. J Am Acad Dermatol. 2020 Nov;83(5):1282-1293 - PubMed
  29. N Engl J Med. 2016 Dec 15;375(24):2335-2348 - PubMed
  30. J Immunol. 2007 Dec 15;179(12):8180-90 - PubMed
  31. J Allergy Clin Immunol. 2006 Jan;117(1):169-75 - PubMed
  32. Allergy. 2018 Apr;73(4):744-764 - PubMed
  33. J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1996-2003.e1 - PubMed
  34. J Exp Med. 1988 Sep 1;168(3):853-62 - PubMed
  35. J Immunol. 1998 Apr 1;160(7):3555-61 - PubMed
  36. J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1 - PubMed
  37. J Allergy Clin Immunol. 2016 Feb;137(2):452-461.e9 - PubMed
  38. J Allergy Clin Immunol. 2016 Feb;137(2):339-349.e10 - PubMed
  39. Curr Treat Options Allergy. 2018;5(3):275-290 - PubMed
  40. Expert Rev Clin Immunol. 2017 May;13(5):425-437 - PubMed
  41. Clin Exp Allergy. 2021 Feb;51(2):329-338 - PubMed
  42. J Allergy Clin Immunol. 2010 Mar;125(3):569-74, 574.e1-574.e7 - PubMed
  43. Immunol Allergy Clin North Am. 2020 Feb;40(1):25-39 - PubMed
  44. Allergy. 2004 Jul;59(7):709-17 - PubMed

Publication Types